Bio-Gene Technology Ltd
ASX:BGT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bio-Gene Technology Ltd
Net Issuance of Common Stock
Bio-Gene Technology Ltd
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Bio-Gene Technology Ltd
ASX:BGT
|
Net Issuance of Common Stock
AU$2.5m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Nufarm Ltd
ASX:NUF
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Parkway Corporate Ltd
ASX:PWN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Terragen Holdings Ltd
ASX:TGH
|
Net Issuance of Common Stock
AU$1.5m
|
CAGR 3-Years
199%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
|
Trigg Mining Ltd
ASX:TMG
|
Net Issuance of Common Stock
AU$7.8m
|
CAGR 3-Years
29%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
R
|
RLF AgTech Ltd
ASX:RLF
|
Net Issuance of Common Stock
AU$3.6m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bio-Gene Technology Ltd
Glance View
Bio-Gene Technology Ltd. is a development company enabling the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-29. The Company’s principal activity is to develop and commercialize insecticide products. The company is focused on enabling novel insecticides to address the global problem of insecticide resistance and toxicity. Its novel platform technology is based on naturally occurring beta-triketones. The Company’s lead beta-triketone insecticide products include Flavocide and Qcide. Flavocide is a synthetically produced nature-identical compound. Testing of Flavocide has been undertaken and continues to be performed by both government research laboratories as well as by commercial collaborators. Qcide natural oil with high levels of tasmanone. The oil is extracted from the leaves of the Gympie Messmate, by utilizing a steam distillation process.
See Also
What is Bio-Gene Technology Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
2.5m
AUD
Based on the financial report for Dec 31, 2025, Bio-Gene Technology Ltd's Net Issuance of Common Stock amounts to 2.5m AUD.
What is Bio-Gene Technology Ltd's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-3%
The average annual Net Issuance of Common Stock growth rates for Bio-Gene Technology Ltd have been 16% over the past three years , -3% over the past five years .
